Analysis of changes in CASP7 AND CHEK1 genes expression in liver toxic damage induced by tetrachloromethane against the background of hepatoprotectors

Cover Page

Cite item

Full Text

Abstract

Introduction. The effect of hepatoprotectors on the expression of genes involved in the regulation of apoptosis and the cell cycle (Casp7 and Chek1) under the toxic effects of carbon tetrachloride (carbon tetrachloride, CCl4) was studied.

Material and methods. Studies were performed in male albino mongrel rats (n=70), assigned to the control group, modulated with CCl4-induced toxic hepatitis and three experimental ones in which the administration of drugs (Heptor, Mexidol and Methyluracil) was carried out 1 hour before CCl4 administration. After 24 and 72 h of CCl4 administration animals were decapitated and the liver was removed. The expression of Casp7 and Chek1 genes in rat liver was studied by real-time using polymerase chain reaction with reverse transcription.

Results. Toxic damage to the liver of rats receiving CCl4 after 24 h resulted an increase in the expression of the Chek1 gene. The use of hepatoprotective drugs practically did not alter the expression of the Casp7 and Chek1 genes relative to the group that received only CCl4. At the same time, when comparing the effect of Mexidol, there were significant differences in the expression of the genes under study between two time points of 24 and 72 h. The effect of Heptor revealed changes in the expression level of the Casp7 gene when comparing the results 24 and 72 h after administration.

Conclusion. The administration of hepatoprotectors to animals receiving CCl4 did not significantly affect the transcriptional activity of the Casp7 and Chek1 genes.

About the authors

Guzel F. Mukhammadieva

Ufa Research Institute of Occupational Health and Human Ecology

Author for correspondence.
Email: ufniimt@mail.ru
ORCID iD: 0000-0002-7456-4787

MD, Ph.D., senior researcher of the department of toxicology and genetics with an experimental clinic of laboratory animals Ufa Research Institute of Occupational Health and Human Ecology, Ufa, 450106, Russian Federation.

e-mail: ufniimt@mail.ru

Russian Federation

T. G. Kutlina

Ufa Research Institute of Occupational Health and Human Ecology

Email: noemail@neicon.ru
ORCID iD: 0000-0002-1236-8246
Russian Federation

D. O. Karimov

Ufa Research Institute of Occupational Health and Human Ecology

Email: noemail@neicon.ru
ORCID iD: 0000-0003-0039-6757
Russian Federation

Ya. V. Valova

Ufa Research Institute of Occupational Health and Human Ecology

Email: noemail@neicon.ru
ORCID iD: 0000-0001-6605-9994
Russian Federation

E. F. Repina

Ufa Research Institute of Occupational Health and Human Ecology

Email: noemail@neicon.ru
ORCID iD: 0000-0001-8798-0846
Russian Federation

N. Yu. Khusnutdinova

Ufa Research Institute of Occupational Health and Human Ecology

Email: noemail@neicon.ru
ORCID iD: 0000-0001-5596-8180
Russian Federation

References

  1. Kutsenko S.A. Bases of toxicology: scientific and methodical edition. [Osnovy toksikologii: nauchno-metodicheskoe izdanie]. St. Petersburg: Foliant; 2004. 570 p. (in Russian)
  2. Antonenko O.M. Hepatotoxicity: options for pharmacological correction. Meditsinskiy sovet. 2013; (6): 45–51. (in Russian)
  3. Weber L.W., Boll M., Stampfl A. Hepatotoxity and mechanism of action of haloalcanes: carbon tetrachloride as a toxicological model. Crit Ref Toxicol. 2003; 33 (2): 105–36.
  4. Shabanov P.D., Soultanov V.S., Lebedev V.A., Bychkov E.R., Proshin S.N. Effects of polyprenol drug ropren in a model of subacute hepatosis with encephalopathy in rats: study of functional state of the liver, behavior and monoamines turnover in the brain. Obzory po klinicheskoy farmakologii i lekarstvennoy terapii. 2010; 8 (3): 7–30. (in Russian)
  5. Kravchenko L.V., Trusov N.V., Uskova M.A., Aksyonov I.B., Avrenyeva L.I., Guseva G.V. et al. Characterization of carbon tetrachloride acute toxicity as a model of oxidative stress. Toksikologicheskiy vestnik. 2009; (1): 12–7. (in Russian)
  6. Katikova O.J., Ruzov V.I., Smirnov L.D. Correction by 2-ethyl-6-methyl-3-hydroxypyridine succinat of the gepatotoxyc, caused at rats introduction тuberculostatics. Biomeditsinskaya khimiya. 2004; 50 (6): 600–4. (in Russian)
  7. Ragulina V.A., Pokrovsky M.V., Orlova E.A., Konoplya A.I., Avdeeva E.V. Loktionov A.L. Antioxidatic effects of derivatives 3-gidroksipiridina in norm and at the acute tetrachlormethane hepatopathies. Kubanskiy nauchnyy meditsinskiy vestnik. 2010; (7): 124–7. (in Russian)
  8. Bakirov A.B., Myshkin V.A., Repina E.F., Karimov D.O., Gimadieva A.R., Timasheva G.V. et al. Overcoming the hepatotoxicity of persistent organic pollutants: the role of antioxidants of pyrimidine structure. Gigiena truda i meditsinskaya ekologiya. 2016; 52 (3): 3–18. (in Russian)
  9. Fuchs Y., Steller H. Programmed cell death in animal development and disease. Cell. 2011; 147 (4): 742–58.
  10. Lamkanfi M., Kanneganti T.D. Caspase-7: a protease involved in apoptosis and inflammation. Int J Biochem Cell Biol. 2010; 42 (1): 21–4.
  11. Li F., Huang Q., Chen J., Peng Y., Roop D.R., Bedford J.S. et al. Apoptotic cells activate the «phoenix rising» pathway to promote wound healing and tissue regeneration. Sci Signal. 2010; 3 (110): ra13. https://doi.org/10.1126/scisignal.2000634
  12. Chandler J.M., Cohen G.M., MacFarlane M. Different subcellular distribution of caspase-3 and caspase-7 following Fas-induced apoptosis in mouse liver. J Biol Chem. 1998; 273 (18): 10815–8.
  13. Smith J., Tho L.M., Xu N., Gillespie D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010; 108: 73–112.
  14. Beck H., Nähse V., Larsen M.S., Groth P., Clancy T., Lees M. et al. Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. J Cell Biol. 2010; 188 (5): 629–38.
  15. Wang K., Lin B. Pathophysiological Significance of Hepatic Apoptosis. ISRN Hepatol. 2012; 2013: 740149. https://doi.org/10.1155/2013/740149
  16. Ogata S., Takeuchi M., Fujita H., Shibata K., Okumura K., Taguchi H. Apoptosis induced by nicotinamide-related compounds and quinolinic acid in HL-60 cells. Biosci Biotechnol Biochem. 2000; 64 (2): 327–32.
  17. Yuan J., Yankner B.A. Apoptosis in the nervous system. Nature. 2000; 407 (6805): 802–9.
  18. Riedl S.J., Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004; 5 (11): 897–907.
  19. Nicholson D.W. From bench to clinic with apoptosis-based therapeutic agents. Nature. 2000; 407 (6805): 810–6.
  20. Hayakawa Y., Chandra M., Miao W., Shirani J., Brown J.H., Dorn G.W. 2nd et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation. 2003; 108 (24): 3036–41.
  21. Vandenabeele P., Galluzzi L., Vanden Berghe T., Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010; 11 (10): 700–14.
  22. Kaiser W.J., Upton J.W., Long A.B., Livingston-Rosanoff D., Daley-Bauer L.P., Hakem R. et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature. 2011; 471 (7338): 368–72.
  23. Liedtke C., Bangen J.M., Freimuth J., Beraza N., Lambertz D., Cubero F.J. et al. Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology. 2011; 141 (6): 2176–87.
  24. Woolbright B.L., Ding W.X., Jaeschke H. Caspase inhibitors for the treatment of liver disease: friend or foe? Expert Rev Gastroenterol Hepatol. 2017; 11 (5): 397–9.
  25. Woolbright B.L., Jaeschke H. Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure. J Hepatol. 2017; 66 (4): 836-848.
  26. Szabo G., Csak T. Inflammasomes in liver diseases. J Hepatol. 2012; 57 (3): 642–54.
  27. Reinhardt H.C., Yaffe M.B. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol. 2009; 21 (2): 245–55.
  28. Sakurikar N., Eastman A. Will targeting Chk1 have a role in the future of cancer therapy? J Clin Oncol. 2015; 33 (9): 1075–7.
  29. Calvo E., Chen V.J., Marshall M., Ohnmacht U., Hynes S.M., Kumm E. et al. Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Invest New Drugs. 2014; 32 (5): 955–68.
  30. Daud A.I., Ashworth M.T., Strosberg J., Goldman J.W., Mendelson D., Springett G. et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015; 33 (9): 1060–6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Mukhammadieva G.F., Kutlina T.G., Karimov D.O., Valova Y.V., Repina E.F., Khusnutdinova N.Y.


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 37884 от 02.10.2009.